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were excluded. RESULTS: The included studies were varied in
focus, study design and conclusions. They researched the impact
of different types of incentives examining their ability to attract
donors and maintain blood safety by preventing disease trans-
mission. Commonly mentioned incentives were free medical
tests, blood credits, paid time off and tickets to events, such as
concerts. The success of incentives to attract donors is dependent
upon age with younger donors being more receptive to most
incentives than older donors. However, offering free cholesterol
and PSA screening also motivates older donors. Using these types
of medical tests as incentives is unlikely to detrimentally affect
blood safety. However, there is considerable debate concerning
the use of incentives with monetary value. There are data
showing that the safety of donated blood is not adversely
affected by such incentives, but there are also data showing a
high response to such incentives by high-risk donors who donate
in order to receive HIV testing. CONCLUSIONS: The positive
impact of incentives with monetary value is limited by their
appeal to donors from high-risk groups. However, if blood incen-
tive programmes are organised at regional or communal levels
as opposed to national levels it may be possible to take advan-
tage of their appeal to younger donors in areas with low levels
of HIV-risk behaviours.
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OBJECTIVES: To evaluate the clinical signiﬁcance of a greater
area under the hemoglobin change curve (Hb AUC) value during
epoetin alfa (EPO) treatment. METHODS: Datasets from two
EPO trials were used (Study 1: N = 2964; Study 2: N = 2289).
Initial EPO regimens were: Study 1: 40,000IU once weekly
(QW), Study 2: 10,000IU thrice weekly (TIW). Each study
allowed for potential dose escalation to 60,000IU QW and
20,000IU TIW respectively. Patients were *0.35618 years, had
a baseline Hb of £11g/dL, and received concomitant chemother-
apy. Outcome measures included: blood transfusions, quality of
life (QoL) measured by Linear Analog Scale Assessment and
Functional Assessment of Cancer Therapy Anemia and Fatigue,
drug utilization and hematopoietic response. All missing values
were imputed based on a last-value-carried-forward principle.
Hb AUC values (g/dL) from baseline to 16 weeks were stratiﬁed
into ﬁve groups established based on data frequency distribu-
tions and clinical judgment (Hb AUC 1: <11; Hb AUC 2: 11 –
< 18; Hb AUC 3: 18 – < 25; Hb AUC 4: 25 – < 32; Hb AUC 5:
> 32). RESULTS: Mean Hb AUCs were similar (Study 1: 19.7
g/dL, Study 2: 21.3g/dL). For Hb AUC groups 1–5 respectively,
the following signiﬁcant trends were observed for patients with
greater Hb AUC values: decreased transfusion use (%) (Study 1:
41, 24, 15, 14, 10; Study 2: 46, 33, 24, 21, 15), increased QoL
across all domains, reduced weekly dose (IU) (Study 1: 45,934,
45,130, 42,596, 41,021, 39,478; Study 2: 38,643, 37,752,
35,011, 33,853, 31,459) and improved hematopoietic response
(%) (Study 1: 13, 54, 85, 98, 100; Study 2: 8, 52, 79, 96, 100).
CONCLUSIONS: Hb AUC is a comprehensive efﬁcacy measure
reﬂecting Hb change over the entire treatment course. Greater
Hb AUC values are associated with a reduction in transfusion
requirements, improved QoL and drug utilization outcomes,
conﬁrming its clinical signiﬁcance.
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OBJECTIVE: To formulate a more comprehensive and general-
izable model than is currently available that fully accounts for
costs associated with blood transfusions. METHODS: A con-
sensus panel of experts in transfusion medicine was organized
by the Society for the Advancement of Blood Management
(SABM), representing clinical, blood banking, and academic
interests. An iterative process was used to reﬁne data from work-
sheets that had been distributed, collected, and summarized prior
to the conference. RESULTS: A detailed process-ﬂow model was
constructed, encompassing both direct and indirect cost ele-
ments. Major steps and critical interdependencies were identi-
ﬁed, including donor recruitment/qualiﬁcation, blood collection,
blood component processing, laboratory testing, unit tracking
and labeling, blood destruction, donor notiﬁcation and tracking,
blood center/collection facility inventory, storage, and transport,
transfusion service inventory and storage, pretransfusion prepa-
ration, transfusion administration and follow-up, and long-term
outcomes tracking. Within these major steps, 248 cost elements
were itemized. The relative importance and degree of difﬁculty
associated with collecting cost data for each element were rated.
Panelists rated personnel, screening for infectious agents, infor-
mation systems, laboratory evaluations, transfusion reaction
management, and equipment as the most important elements to
capture. Limitations in current process-ﬂow models were recog-
nized, with deﬁciencies in accounting for both direct and indi-
rect costs. Work is in progress to convert the present model into
one that employs activity-based costing (ABC) which will correct
the underestimates of blood costs provided in existing literature.
CONCLUSIONS: Accounting for the cost of blood is an enor-
mously complex undertaking and a standard, widely applicable
methodology is needed. As presented, this process-ﬂow diagram
and comprehensive set of cost elements should be of interest to
providers, payers, and society. When completed, the ABC model
will be a more precise means to compare the cost of blood to
that of transfusion alternatives or for evaluating safety-related
improvements to blood administration technology.
